Adaptive Biotechnologies, a Seattle, WA-based developer of immunosequencing diagnostics, with a focus on oncology, completed $105m Series C and D financing rounds.
Viking Global Investors contributed $5m to close out the Series C round and $100m in the Series D round and will take an observer seat on Adaptive’s Board.
The company intends to use the funds to expand globally its platform and launch its products.
Led by Chad Robins, CEO and Founder, Adaptive Biotechnologies develops an immunosequencing research platform (immunoSEQTM) and diagnostic products for the treatment of cancer, autoimmune disorders, and infectious diseases. Its first diagnostic product, clonoSEQTM, monitors relapse in patients with certain blood cancers. The company is also involved in validating and launching an assay called quanTILfyTM, which interrogates Tumor Infiltrating Lymphocytes in solid tumors for prognosis and as a potential predictive biomarker of response to treatment with cancer immunotherapies.
FinSMEs
07/04/2014